Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy: A nationwide, population-based cohort study

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Lin, Chien Ming ^a,b   Huang, Hui Ling ^c   Chu, Fang Ying ^c   Fan, Hueng Chuen ^a   Chen, Hung An ^c   Chu, Der Ming ^a   Wu, Li Wei ^a,b   Wang, Chung Ching ^a,b   Chen, Wei Liang ^a,b   Lin, Shih Hua ^a   Ho, Shinn Ying ^c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSIDASE INHIBITOR; LONG ACTING INSULIN;

ADULT; ANTIDIABETIC THERAPY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GOUT; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; INSULIN TREATMENT; LIVER CANCER; LIVER CIRRHOSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH CANCER; OBESITY; PANCREAS CANCER; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK REDUCTION; TAIWAN; YOUNG ADULT; COLORECTAL NEOPLASMS; INCIDENCE; LIVER NEOPLASMS; PANCREATIC NEOPLASMS;

ADULT; COHORT STUDIES; COLORECTAL NEOPLASMS; DIABETES MELLITUS; FEMALE; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN, LONG-ACTING; LIVER NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAIWAN; YOUNG ADULT;

EID: 84929339047     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125421     Document Type: Article

References (35)

1. Jiang YD, Chang CH, Tai TY, Chen JF, Chuang LM. Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000-2009 Nationwide Health Insurance database. J Formos Med Assoc. 2012; 111: 599-604. doi: 10.1016/j.jfma.2012.09.014 PMID: 23217595
2. Ministry of Health and Welfare, Taiwan. Cause of death statistics. 2012; Available: www.mohwgovtw/cht/DOS/Statisticaspx?f-list-no=312&fod-list-no=2747 Accessed 4 June 2013.
3. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33: 1674-1685. doi: 10.2337/dc10-0666 PMID: 20587728
4. Lee MY, Lin KD, Hsiao PJ, Shin SJ. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism. 2012; 61: 242-249. doi: 10.1016/j.metabol.2011.06.020 PMID: 21820134
5. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8: 915-928. doi: 10.1038/nrc2536 PMID: 19029956
6. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 2007; 67: 391-397. PMID: 17210722
7. Mardilovich K, Pankratz SL, Shaw LM. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal. 2009; 7: 14. doi: 10.1186/1478-811X-7-14 PMID: 19534786
8. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001; 131: 3109S-3120S. PMID: 11694656
9. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029-1033. doi: 10.1126/science.1160809 PMID: 19460998
10. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2569-2578. doi: 10.1158/1055-9965.EPI-09- 0372 PMID: 19755644
11. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7, 12-dimethylbenz(a)anthracene- induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res. 1972; 32: 226-232. PMID: 5058183
12. Administration NHI, Ministry of Health and Welfare, Taiwan. Statistical annual reports. Available: www.nhigovtw/webdata/webdataaspx?menu=17&menu-id=1023&WD-ID=1043&webdata-id=3351.
13. Welfare MoHa, Taiwan. Cancer registry annual report. 2010; Available: www.hpagovtw/BHPNet/Web/Stat/StatisticsShowaspx?No=201305060001 Accessed 6 May 2013.
14. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012; 107: 46-52. doi: 10.1038/ajg.2011.384 PMID: 22085817
15. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol. 2009; 15: 2506-2511. PMID: 19469001
16. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010; 116: 1938-1946. doi: 10. 1002/cncr.24982 PMID: 20166205
17. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305. PMID: 15849206
18. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 254-258. PMID: 16443869
19. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766-1777. doi: 10.1007/s00125-009-1440-6 PMID: 19572116
20. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009; 46: 279-284. doi: 10.1007/s00592-008-0083-2 PMID: 19082520
21. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population- based case-control study. Cancer Causes Control. 2009; 20: 1617-1622. doi: 10.1007/s10552- 009-9407-y PMID: 19653109
22. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3: 1451-1461. doi: 10.1158/1940-6207.CAPR-10-0157 PMID: 20947488
23. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010; 33: 1304-1308. doi: 10.2337/dc09-1791 PMID: 20299480
24. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010; 33: 322-326. doi: 10. 2337/dc09-1380 PMID: 19918015
25. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer. 2011; 11: 20. doi: 10.1186/1471-2407-11-20 PMID: 21241523
26. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66: 10269-10273. PMID: 17062558
27. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8: 909-915. PMID: 19221498
28. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009; 8: 2031-2040. PMID: 19440038
29. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67: 10804-10812. PMID: 18006825
30. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 2008; 15: 833-839. doi: 10. 1677/ERC-08-0038 PMID: 18469156
31. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27: 3576-3586. doi: 10.1038/sj.onc.1211024 PMID: 18212742
32. Jonasson JM1, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009; 52: 1745-1754. doi: 10.1007/s00125-009-1444-2 PMID: 19588120
33. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009; 52: 1732-1744. doi: 10.1007/s00125-009-1418-4 PMID: 19565214
34. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367: 319-328. doi: 10. 1056/NEJMoa1203858 PMID: 22686416
35. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2147-2153. PMID: 16172224